Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

SECURE Synthetic Gene Circuits for Closed-loop Therapy

Coordinator
Ruprecht-Karls-Universitaet Heidelberg, Germany
Runs
1 February 2026 to 31 January 2029
Status
Running
EU funding
€3.0m
Total cost
€3.0m
Partners
6 organisations in 5 countries
Type
European Innovation Council
Grant agreement
101257261

What the project is doing

In the project's own words, from its summary on CORDIS.

What if gene therapy could think, adapt, and act only when needed? SECURE sets out to create the world’s first self-adaptive gene therapy platform ‒ a transformative leap from today’s static interventions toward programmable, intelligent therapeutics. Rather than permanently active vectors, our approach uses synthetic gene circuits that remain dormant under healthy conditions and activate only in cells exhibiting disease-induced molecular stress.

This ""on-demand"" precision therapy promises unprecedented safety, efficacy, and personalisation. As a first-in-class application, SECURE targets Parkinson’s Disease (PD) by focusing on vulnerable dopaminergic neurons identified through stress markers such as AGTR1 expression, inflammation, and oxidative damage. Using AI-guided design, we will engineer AAV and bocavirus vectors tailored for efficient blood-brain barrier (BBB) transcytosis and neuron-specific targeting, guided by human receptor maps from neurotropic viruses.

Validation will rely exclusively on human iPSC-derived midbrain organoids ‒ including mosaic models combining healthy and PD genotypes ‒ to test selectivity, reversibility, and safety. A closed-loop development pipeline will be established, where data from single-cell transcriptomics, electrophysiology, and functional assays continually refine vector design through AI feedback. By integrating synthetic biology, AI, and advanced disease modelling, SECURE pioneers a new therapeutic paradigm for neurodegeneration and potentially for multifactorial and hereditary diseases at large.

If successful, it will mark the beginning of preventative, adaptive, and lifelong gene therapy for complex human disorders.""

Topics

Who is involved

OrganisationCityCountryRole
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyCoordinator
Pharmacoidea Fejleszto Es Szolgaltato KftSzegedHungaryParticipant
Tel Aviv UniversityTel AvivIsraelParticipant
Organotherapeutics GmbHEsch-Sur-AlzetteLuxembourgParticipant
Cardiff UniversityCardiffUnited KingdomParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI